Stephanie O'Brien - Jan 1, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Director
Signature: /s/ David Watson, attorney-in-fact for Stephanie Monagham O'Brien
Stock symbol: APLS
Transactions as of: Jan 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 1/4/2022, 03:41 PM
Next filing: Jan 4, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Award	$0	+4.23K		$0.00	4.23K	Jan 1, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$0	+8.55K		$0.00	8.55K	Jan 1, 2022	Common Stock	8.55K	$47.28	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents a restricted stock unit grant made on 1/1/2022 that fully vest on the first anniversary of the date of grant, subject to continued service as a director.
F2	This represents a non-qualified stock option grant made on 1/1/2022 that vests quarterly over 1 year from the date of grant, subject to continued service as a director, and expires seven years from the date of grant.